PF-05175157 is primarily investigated for its potential therapeutic applications in the treatment of metabolic disorders, particularly those related to lipid metabolism. It functions as an acetyl-CoA carboxylase (ACC) inhibitor, which plays a critical role in fatty acid synthesis and oxidation. By inhibiting ACC, this compound helps reduce fatty acid synthesis and promotes fatty acid oxidation, making it a promising candidate for managing conditions like non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Research is ongoing to evaluate its efficacy and safety in clinical settings, with the aim of developing targeted therapies for metabolic syndrome and related complications.